After a Positive Self-Collected HPV Test: When Is Colposcopy Needed?

How HPV genotype, cervical triage and screening history determine the next clinical step.

A positive result from a self-collected vaginal HPV test does not automatically mean that a patient needs colposcopy. Under the US recommendations from the American Society for Colposcopy and Cervical Pathology (ASCCP), HPV 16 or 18 positivity leads directly to colposcopy. Several other high-risk HPV results require clinician-collected cervical cytology or p16/Ki-67 dual-stain testing first. An isolated positive result for HPV 56/59/66, with no other carcinogenic HPV types detected, is managed with repeat HPV testing in one year [1].

The next step depends on the genotype detected, the assay's reporting format and the patient's screening history. Because a vaginal self-collected specimen does not directly sample cervical cells, some positive results require an additional clinical visit to obtain a cervical specimen.

The pathway below focuses on US guidance for routine screening. It should not be applied automatically to every country or to patients undergoing surveillance after previous cervical abnormalities or treatment.

What a Vaginal Self-Sample Can—and Cannot—Provide

Self-collected HPV testing allows an individual to obtain a vaginal specimen without a speculum examination at the initial screening visit. When used with an authorized collection device and HPV assay, the sample can be tested for high-risk human papillomavirus.

The limitation becomes relevant when the result is positive. Conventional cervical cytology and p16/Ki-67 dual-stain testing require cervical cells, which are not directly collected by a vaginal self-sampling device.

A clinician-collected cervical specimen provides additional testing options. Depending on the laboratory's workflow, HPV testing and reflex cytology or dual-stain testing can be performed using material from the same cervical collection. This may avoid a second visit when further assessment is needed [1,2].

For a patient whose self-collected test is positive, the immediate next step therefore depends on the HPV result:

• HPV 16 or 18: proceed to colposcopy, with cervical cytology collected at the examination.

• Other specified high-risk genotypes: obtain a clinician-collected cervical specimen for cytology or dual-stain triage.

• Isolated HPV 56/59/66, with no other carcinogenic types: repeat HPV testing in one year; immediate cervical triage is not required under this recommendation.

The last category is an important exception. Not every positive self-collected result requires an immediate speculum examination.

How HPV Genotype Determines the Next Step

The 2025 ASCCP Enduring Consensus recommendations provide specific management guidance for positive self-collected vaginal HPV results [1].

US ASCCP follow-up recommendations

These recommendations apply to the specified US screening pathway and should be interpreted according to the assay used and the patient's previous results [1].

What happens after cervical triage?

For patients who need additional cervical testing, the result of cytology or dual-stain testing determines whether colposcopy is required.

When cytology and dual-stain testing are performed together, high-grade cytology findings such as ASC-H, AGC or HSIL still require colposcopy even if the dual-stain result is negative [1].

If a patient with negative triage testing undergoes repeat HPV testing at one year, detection of any HPV type leads to colposcopy under the specified pathway.

For an initial result showing only HPV 56/59/66, repeat HPV testing is recommended in one year. If any HPV type is detected at that follow-up, colposcopy is recommended.

Why the HPV Assay's Genotype Report Matters

The genotype result must be interpreted according to the actual reporting channels of the HPV test. A laboratory report showing pooled high-risk HPV positivity does not necessarily identify which individual types are present.

The differences between three FDA-authorized platforms illustrate this point [2,3].

For example, a patient with a positive Abbott Other HR HPV B result may have HPV 35, 39, 51, 56, 59, 66 or 68. The report does not distinguish these types individually. The one-year repeat-testing recommendation for isolated HPV 56/59/66 cannot be applied to that pooled result without additional genotype information.

The same issue arises with Roche cobas, where the pooled other high-risk HPV result does not identify HPV 56/59/66 separately.

Collection conditions also matter. The FDA authorizes specific combinations of collection devices, assays and specimen settings. For example, the Abbott Alinity m supplement P230003/S006 permits self-collected vaginal specimens obtained in a healthcare setting as an alternative when cervical sampling is contraindicated or a cervical specimen otherwise cannot be obtained [3]. Authorization for one device or testing platform should not be generalized to other combinations.

What Recent Clinical Studies Tell Us

Two studies published in 2025 and 2026 provide useful evidence about self-collected HPV testing. One examined agreement between different sample types; the other evaluated screening participation and follow-up in a US safety-net healthcare system.

Vaginal self-collection compared with clinician-collected samples

Ho and colleagues conducted a prospective study at a tertiary colposcopy clinic in Hong Kong. The study included 167 premenopausal women referred because of abnormal Pap results. Participants provided self-collected vaginal, urine and menstrual blood samples, alongside clinician-collected cervical specimens [6].

The agreement between clinician-collected and self-collected vaginal samples for high-risk HPV detection was 83.2%. Of the 167 participants, 139 underwent colposcopy, and 42 had HSIL+ identified.

For detecting HSIL, the relative sensitivity of self-collected vaginal HPV testing compared with clinician-collected cervical HPV testing was 0.89 (95% CI, 0.79–1.02).

The confidence interval includes 1.0, so the study did not demonstrate a statistically significant difference between the two methods. This should not be interpreted as proof of equivalence.

The study population also needs to be considered. These were women already referred to a tertiary colposcopy clinic because of abnormal cytology, rather than an average-risk population undergoing routine screening. In addition, not all participants underwent colposcopy and biopsy. The findings therefore cannot be used as a direct estimate of self-collection performance in a general screening population [6].

PRESTIS: Screening participation and follow-up after a positive result

The PRESTIS randomized clinical trial, published in JAMA Internal Medicine in 2025, examined whether mailed self-collection kits could increase cervical cancer screening participation among underscreened individuals in a publicly funded safety-net healthcare system in Houston, Texas [7].

A total of 2,474 participants were randomized into three groups. At six months, screening participation was:

The mailed self-collection option substantially increased participation compared with a telephone reminder alone. Additional patient navigation produced a more modest increase [7].

The follow-up results show why the initial screening result cannot be treated as the end of the process.

Among 609 participants who returned a self-collection kit, 84 (13.8%) had a positive high-risk HPV result requiring further assessment. Of these, 77 needed cytology and seven were referred directly for colposcopy.

Follow-up was completed by 22 of 36 patients (61.1%) in the self-collection group and 33 of 48 patients (68.8%) in the self-collection-plus-navigation group [7].

The trial was not powered to establish a reliable difference in follow-up completion between these smaller subgroups. There is also an important assay limitation: the study used the Aptima HPV mRNA assay on self-collected specimens. The investigators noted that this assay had lower sensitivity on self-collected samples than DNA-based tests and was not FDA-approved for self-collection at the time of the trial. The FDA approval for self-collected specimens in healthcare settings came after the study was completed [7].

The PRESTIS results are therefore valuable for understanding screening participation and follow-up logistics, but should not be presented as direct validation of all currently authorized self-collection test combinations.

Managing Positive Results and Repeat Testing

Clinics offering self-collected HPV screening need a defined process for handling results before the first sample is collected.

The ASCCP's October 2025 practice advisory emphasizes accurate patient contact information, standardized result tracking and clear communication of follow-up instructions. Appointment scheduling assistance and patient navigation can also help patients complete the next stage of assessment [2].

The clinic's workflow should distinguish between three different situations:

Direct colposcopy referral

Patients with HPV 16 or 18 positivity should be referred for colposcopy. Cervical cytology is collected at the examination, and biopsy is performed according to the clinical findings and applicable colposcopy standards.

Cervical triage

Patients with other specified high-risk HPV results or untyped/pooled positive results generally need a clinician-collected cervical specimen for cytology or dual-stain testing. The triage result determines whether colposcopy or repeat HPV testing is appropriate.

Scheduled repeat testing

Patients with isolated HPV 56/59/66 positivity and no other carcinogenic types, or those with negative cervical triage results, enter a one-year repeat-testing schedule.

These groups should not be managed through the same appointment or recall process. A positive laboratory report needs to be linked to a documented next action, and patients who are due for repeat testing need to remain in the clinic's follow-up system.

Where Video Colposcopy Fits After HPV Triage

When a patient meets the criteria for colposcopy, the clinician examines the cervix more closely, particularly the transformation zone. Acetic acid is applied to help identify epithelial changes, and suspicious areas can be selected for directed biopsy. Histopathological examination of collected tissue establishes the diagnosis when biopsy is indicated.

A video colposcope provides magnified cervical visualization and monitor-based image display during the examination. It supports clinical observation and communication, but does not detect HPV, identify viral genotypes or independently confirm cervical precancer.

KernelMed's KN-2200IH Full HD Video Colposcope is designed for gynecological examination and cervical assessment. Its published specifications include:

• 3.27 million effective pixels

• 1920 × 1080 image size

• 30× optical zoom

• Four imaging modes

• Optional dual-screen configuration

The dual-screen option allows the clinician and patient to view examination images during consultation. The imaging and magnification specifications describe the equipment's visualization capabilities; they should not be interpreted as evidence of improved HPV detection or CIN3+ diagnostic accuracy.

For clinics evaluating monitor-based colposcopy systems, see the KN-2200IH Full HD Video Colposcope.

Our earlier article, Video Colposcopy in the HPV Screening Era, discusses the equipment's role in cervical examination and clinical workflow. A separate discussion of CIN3+ risk stratification in colposcopy referrals examines how referral findings and screening history influence the assessment of patients referred for colposcopy.

Which Screening Guidelines Should Clinics Follow?

The genotype-specific management described above is based on US ASCCP recommendations. Other screening programmes may use different age criteria, genotyping strategies and follow-up intervals.

The American Cancer Society's 2026 guideline update accepts self-collected vaginal specimens as an alternative for average-risk individuals aged 25–65 years when the HPV assay, collection device and setting meet the relevant FDA authorization. Clinician-collected cervical specimens remain preferred, and a three-year interval is recommended after a negative self-collected HPV screening result [4].

ACOG Committee Statement No. 28, published in July 2026, endorses the updated Women's Preventive Services Initiative recommendations. For average-risk individuals aged 30–65 years, patient-collected primary high-risk HPV screening every three years may be considered when FDA-approved testing kits and appropriate systems for result notification and follow-up are available [5].

The World Health Organization's 2021 guideline supports the use of either provider-collected or self-collected samples for HPV DNA testing within appropriate screening programmes [8]. Its 2026 guideline on HPV DNA genotyping further addresses partial and extended genotyping as approaches to risk stratification and molecular triage, with implementation adapted to national programme capacity [9]. These WHO recommendations provide a global programme framework; they are not a replacement for the US ASCCP algorithm described in this article.

The routine screening pathway should also be distinguished from surveillance and diagnostic assessment. Patients with symptoms such as unexplained vaginal or postcoital bleeding need diagnostic evaluation rather than routine screening management. Patients with HIV, significant immunosuppression or in-utero DES exposure require specific guidance.

For patients undergoing surveillance after abnormal screening results, colposcopy or treatment of cervical precancer, clinician-collected cervical specimens remain preferred. If a clinician-collected specimen cannot be obtained, self-collection may be considered after shared decision-making under the applicable ASCCP guidance, with management following the relevant risk-based recommendations [1,4].

The decision after a positive self-collected HPV test depends on more than the positive label. Genotype, assay reporting, cervical triage findings and previous screening history all influence whether the next step is colposcopy, additional testing or repeat HPV screening.

Frequently Asked Questions

1. Does a positive self-collected HPV test mean that a patient has cervical cancer?

No. A positive result indicates that the assay has detected one or more high-risk HPV types. It does not diagnose cervical precancer or cancer. Further assessment depends on the genotype, screening history and additional test results.

2. Does every positive self-collected HPV result require colposcopy?

No. HPV 16 or 18 positivity leads directly to colposcopy under the US ASCCP pathway. Other specified high-risk results generally require cervical cytology or dual-stain triage first. An isolated HPV 56/59/66 result, with no other carcinogenic types detected, is managed with repeat HPV testing in one year.

3. Why is a clinician-collected cervical sample needed after some positive results?

A self-collected vaginal specimen does not directly sample cervical cells. When cytology or p16/Ki-67 dual-stain testing is required, a clinician must collect a cervical specimen during a speculum examination.

4. What happens if only HPV 56, 59 or 66 is detected?

If the assay specifically identifies the HPV 56/59/66 group and no other carcinogenic HPV types are detected, the US ASCCP recommendation is to repeat HPV testing in one year. A positive result for any HPV type at that follow-up leads to colposcopy under this pathway.

5. Can different HPV tests produce different genotype reports?

Yes. BD Onclarity, Roche cobas and Abbott Alinity m use different genotype reporting channels. Some identify HPV 16 and 18 individually, while others report several high-risk types as pooled groups. The management recommendation must match the information actually provided by the assay.

6. Can a video colposcope detect HPV or confirm cervical precancer?

No. HPV detection is performed by a validated laboratory assay. A video colposcope supports magnified cervical examination and image display. Histopathological examination of a biopsy is used to establish the tissue diagnosis when indicated.

References

1. 1.Wentzensen N, Massad LS, Clarke MA, Garcia F, Smith R, Murphy J, Guido R, Reyes A, Phillips S, Berman N, Quinlan J, Lind E, Perkins RB; Enduring Consensus Cervical Cancer Screening and Management Guidelines Committee. Self-Collected Vaginal Specimens for HPV Testing: Recommendations From the Enduring Consensus Cervical Cancer Screening and Management Guidelines Committee. Journal of Lower Genital Tract Disease. 2025;29(2):144–152.

2. 
   

3. 2.American Society for Colposcopy and Cervical Pathology. ASCCP Practice Advisory: Self Collection for Cervical Cancer Screening. Updated October 2025.
   
   

4. 3.US Food and Drug Administration. Alinity m HR HPV, PMA Supplement P230003/S006. Decision date: September 10, 2025.
   
   

5. 4.Perkins RB, Wolf AMD, Church TR, et al. Self-Collected Vaginal Specimens for Human Papillomavirus Testing and Guidance on Screening Exit: An Update to the American Cancer Society Cervical Cancer Screening Guideline. CA: A Cancer Journal for Clinicians. 2026;76(1).
   
   

6. 5.American College of Obstetricians and Gynecologists. ACOG Committee Statement No. 28: Screening for Cervical Cancer. Obstetrics & Gynecology. 2026;148(1)–e67.
   
   

7. 6.Ho SKD, Liu S, Lau LSK, Cheung ANY, Chu MY, Tse KY, Ngu SF, Chan KKL. HPV Detection in Clinician-Collected, Self-Collected Vagina, Urine, and Menstrual Blood Samples. Journal of Lower Genital Tract Disease. 2026;30(3):169–174.
   
   

8. 7.Montealegre JR, Hilsenbeck SG, Bulsara S, Parker SL, Amboree TL, Anderson ML, Daheri M, Jibaja-Weiss ML, Schmeler KM, Deshmukh AA, Chiao EY, Scheurer ME. Self-Collection for Cervical Cancer Screening in a Safety-Net Setting: The PRESTIS Randomized Clinical Trial. JAMA Internal Medicine. 2025;185(9):1119–1127.
   
   

9. 8.World Health Organization. WHO Guideline for Screening and Treatment of Cervical Pre-Cancer Lesions for Cervical Cancer Prevention. 2nd ed. Geneva: WHO; 2021.
   
   

10. 9.World Health Organization. WHO Guideline for Screening and Treatment of Cervical Pre-Cancer Lesions for Cervical Cancer Prevention: Use of Human Papillomavirus (HPV) DNA Genotyping. Geneva: WHO; 2026.
    
    

Explore KernelMed Video Colposcopy Systems

For clinics providing cervical assessment and colposcopy services, explore KernelMed's digital video colposcopy systems and available configurations.

View KernelMed Video Colposcope Products